ZIOP Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 saus. 2022 @ 07:00):

Stats
Šios dienos apimtis	2.13M
Vidutinė apimtis	2.36M
Rinkos kapitalizacija	208.12M
EPS	$0 ( 2022-02-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.07
ATR14	$0.104 (12.01%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-22	De Groot Eleanor	Sell	20 132	Common Stock
2021-03-04	Thistle Mary	Buy	150 000	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	37 500	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	5 000	Common Stock
2021-03-04	Buchi J Kevin	Buy	31 250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 95 transactions
Buy: 4 516 054 \| Sell: 1 683 458

Tūris Koreliacija

Ilgas: 0.25 (neutral)

Trumpas: 0.41 (neutral)

Signal:(38.327) Neutral

ZIOPHARM Oncology Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
JAGX	0.926
MICS	0.922
FCBC	0.92
ONEM	0.917
BWB	0.915
PSHG	0.914
CVBF	0.91
AROW	0.91
CYRN	0.908
BMRC	0.905

10 Labiausiai neigiamai susiję koreliacijos
ITAQU	-0.963
MCAA	-0.954
OPRA	-0.945
RCEL	-0.941
COCO	-0.939
BRLI	-0.938
ARYD	-0.937
APTM	-0.935
SLAM	-0.935
TZPS	-0.934

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ZIOPHARM Oncology Inc Koreliacija - Valiuta/Žaliavos

-0.22
( neutral )

-0.36
( neutral )

-0.75
( moderate negative )

-0.76
( moderate negative )

-0.63
( weak negative )

0.40
( neutral )

ZIOPHARM Oncology Inc Finansinės ataskaitos

Annual	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2019
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2018
Pajamos:	$146 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

ZIOPHARM Oncology Inc

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.